Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) Stock Competitors & Peer Comparison
See NNNN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NNNN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NNNN | $9.90 | +1.64% | 441.5M | 145.38 | $0.07 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
NNNN vs BDX Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas BDX's P/E ratio is 11.62. In terms of profitability, NNNN's ROE is +0.27%, compared to BDX's ROE of +0.05%. Regarding short-term risk, NNNN is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
NNNN vs BDXA Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas BDXA's P/E ratio is 45.70. In terms of profitability, NNNN's ROE is +0.27%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, NNNN is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
NNNN vs MDLN Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas MDLN's P/E ratio is 45.06. In terms of profitability, NNNN's ROE is +0.27%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, NNNN is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
NNNN vs WST Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas WST's P/E ratio is 41.19. In terms of profitability, NNNN's ROE is +0.27%, compared to WST's ROE of +0.19%. Regarding short-term risk, NNNN is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
NNNN vs HOLX Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas HOLX's P/E ratio is 31.54. In terms of profitability, NNNN's ROE is +0.27%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, NNNN is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
NNNN vs COO Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas COO's P/E ratio is 15.42. In terms of profitability, NNNN's ROE is +0.27%, compared to COO's ROE of +0.03%. Regarding short-term risk, NNNN is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
NNNN vs BDXB Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas BDXB's P/E ratio is 7.60. In terms of profitability, NNNN's ROE is +0.27%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, NNNN is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
NNNN vs BAX Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas BAX's P/E ratio is 10.77. In terms of profitability, NNNN's ROE is +0.27%, compared to BAX's ROE of -0.16%. Regarding short-term risk, NNNN is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
NNNN vs ATR Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ATR's P/E ratio is 23.13. In terms of profitability, NNNN's ROE is +0.27%, compared to ATR's ROE of +0.14%. Regarding short-term risk, NNNN is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
NNNN vs AVTR Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas AVTR's P/E ratio is 13.46. In terms of profitability, NNNN's ROE is +0.27%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, NNNN is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
NNNN vs RGEN Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas RGEN's P/E ratio is 73.31. In terms of profitability, NNNN's ROE is +0.27%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, NNNN is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
NNNN vs TFX Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas TFX's P/E ratio is 12.32. In terms of profitability, NNNN's ROE is +0.27%, compared to TFX's ROE of -0.28%. Regarding short-term risk, NNNN is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
NNNN vs BLCO Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas BLCO's P/E ratio is 24.88. In terms of profitability, NNNN's ROE is +0.27%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, NNNN is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
NNNN vs STVN Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas STVN's P/E ratio is 31.81. In terms of profitability, NNNN's ROE is +0.27%, compared to STVN's ROE of +0.10%. Regarding short-term risk, NNNN is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
NNNN vs MMSI Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas MMSI's P/E ratio is 19.01. In terms of profitability, NNNN's ROE is +0.27%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, NNNN is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
NNNN vs ICUI Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ICUI's P/E ratio is 19.66. In terms of profitability, NNNN's ROE is +0.27%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, NNNN is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
NNNN vs HAE Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas HAE's P/E ratio is 15.86. In terms of profitability, NNNN's ROE is +0.27%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NNNN is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
NNNN vs XRAY Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas XRAY's P/E ratio is 9.04. In terms of profitability, NNNN's ROE is +0.27%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, NNNN is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
NNNN vs LMAT Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas LMAT's P/E ratio is 37.05. In terms of profitability, NNNN's ROE is +0.27%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, NNNN is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
NNNN vs PLSE Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas PLSE's P/E ratio is -27.48. In terms of profitability, NNNN's ROE is +0.27%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, NNNN is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
NNNN vs ATRC Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, NNNN's ROE is +0.27%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, NNNN is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
NNNN vs BLFS Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas BLFS's P/E ratio is -141.85. In terms of profitability, NNNN's ROE is +0.27%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, NNNN is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
NNNN vs AZTA Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas AZTA's P/E ratio is 60.82. In terms of profitability, NNNN's ROE is +0.27%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, NNNN is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
NNNN vs KMTS Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas KMTS's P/E ratio is -8.92. In terms of profitability, NNNN's ROE is +0.27%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, NNNN is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
NNNN vs STAA Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas STAA's P/E ratio is 41.02. In terms of profitability, NNNN's ROE is +0.27%, compared to STAA's ROE of -0.06%. Regarding short-term risk, NNNN is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
NNNN vs QDEL Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas QDEL's P/E ratio is 11.98. In terms of profitability, NNNN's ROE is +0.27%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, NNNN is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
NNNN vs ATRI Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ATRI's P/E ratio is 64.50. In terms of profitability, NNNN's ROE is +0.27%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, NNNN is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
NNNN vs ANGO Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ANGO's P/E ratio is -34.85. In terms of profitability, NNNN's ROE is +0.27%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, NNNN is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ANGO's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
NNNN vs OSUR Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas OSUR's P/E ratio is -4.78. In terms of profitability, NNNN's ROE is +0.27%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, NNNN is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
NNNN vs SMTI Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas SMTI's P/E ratio is -426.00. In terms of profitability, NNNN's ROE is +0.27%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, NNNN is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
NNNN vs UTMD Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas UTMD's P/E ratio is 19.86. In terms of profitability, NNNN's ROE is +0.27%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, NNNN is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
NNNN vs INFU Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas INFU's P/E ratio is 23.97. In terms of profitability, NNNN's ROE is +0.27%, compared to INFU's ROE of +0.14%. Regarding short-term risk, NNNN is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
NNNN vs KRMD Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas KRMD's P/E ratio is -95.75. In terms of profitability, NNNN's ROE is +0.27%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, NNNN is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
NNNN vs PDEX Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas PDEX's P/E ratio is 19.34. In terms of profitability, NNNN's ROE is +0.27%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, NNNN is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
NNNN vs MBOT Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas MBOT's P/E ratio is -6.58. In terms of profitability, NNNN's ROE is +0.27%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, NNNN is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
NNNN vs AKYA Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas AKYA's P/E ratio is -1.34. In terms of profitability, NNNN's ROE is +0.27%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, NNNN is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
NNNN vs STSS Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas STSS's P/E ratio is -0.02. In terms of profitability, NNNN's ROE is +0.27%, compared to STSS's ROE of -1.66%. Regarding short-term risk, NNNN is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
NNNN vs DXR Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas DXR's P/E ratio is 27.33. In terms of profitability, NNNN's ROE is +0.27%, compared to DXR's ROE of +0.22%. Regarding short-term risk, NNNN is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
NNNN vs OMIC Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas OMIC's P/E ratio is -0.58. In terms of profitability, NNNN's ROE is +0.27%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, NNNN is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
NNNN vs IGAP Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas IGAP's P/E ratio is -10.52. In terms of profitability, NNNN's ROE is +0.27%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, NNNN is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
NNNN vs NEPH Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas NEPH's P/E ratio is 50.86. In terms of profitability, NNNN's ROE is +0.27%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, NNNN is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
NNNN vs MLSS Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas MLSS's P/E ratio is -6.50. In terms of profitability, NNNN's ROE is +0.27%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, NNNN is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
NNNN vs POCI Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas POCI's P/E ratio is -6.07. In terms of profitability, NNNN's ROE is +0.27%, compared to POCI's ROE of -0.37%. Regarding short-term risk, NNNN is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
NNNN vs SDC Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas SDC's P/E ratio is -0.03. In terms of profitability, NNNN's ROE is +0.27%, compared to SDC's ROE of -1.96%. Regarding short-term risk, NNNN is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
NNNN vs HBIO Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas HBIO's P/E ratio is -16.81. In terms of profitability, NNNN's ROE is +0.27%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, NNNN is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
NNNN vs IVC Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas IVC's P/E ratio is -0.79. In terms of profitability, NNNN's ROE is +0.27%, compared to IVC's ROE of -0.46%. Regarding short-term risk, NNNN is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
NNNN vs RVP Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas RVP's P/E ratio is -2.06. In terms of profitability, NNNN's ROE is +0.27%, compared to RVP's ROE of -0.08%. Regarding short-term risk, NNNN is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
NNNN vs ZJYL Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, NNNN's ROE is +0.27%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, NNNN is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
NNNN vs FEMY Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas FEMY's P/E ratio is -10.25. In terms of profitability, NNNN's ROE is +0.27%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, NNNN is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
NNNN vs RGNT Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas RGNT's P/E ratio is -0.08. In terms of profitability, NNNN's ROE is +0.27%, compared to RGNT's ROE of N/A. Regarding short-term risk, NNNN is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
NNNN vs NSTG Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas NSTG's P/E ratio is -0.03. In terms of profitability, NNNN's ROE is +0.27%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, NNNN is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
NNNN vs NXGL Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas NXGL's P/E ratio is -1.13. In terms of profitability, NNNN's ROE is +0.27%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, NNNN is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
NNNN vs POAI Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas POAI's P/E ratio is -0.03. In terms of profitability, NNNN's ROE is +0.27%, compared to POAI's ROE of -107.05%. Regarding short-term risk, NNNN is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
NNNN vs LUCY Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas LUCY's P/E ratio is -0.39. In terms of profitability, NNNN's ROE is +0.27%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, NNNN is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
NNNN vs MHUA Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas MHUA's P/E ratio is 0.25. In terms of profitability, NNNN's ROE is +0.27%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, NNNN is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
NNNN vs NXGLW Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, NNNN's ROE is +0.27%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, NNNN is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
NNNN vs GMVD Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas GMVD's P/E ratio is -0.01. In terms of profitability, NNNN's ROE is +0.27%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, NNNN is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
NNNN vs GMVDW Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas GMVDW's P/E ratio is N/A. In terms of profitability, NNNN's ROE is +0.27%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, NNNN is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
NNNN vs AVGR Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas AVGR's P/E ratio is -0.05. In terms of profitability, NNNN's ROE is +0.27%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, NNNN is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
NNNN vs LUCYW Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, NNNN's ROE is +0.27%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, NNNN is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
NNNN vs GCTK Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas GCTK's P/E ratio is -0.01. In terms of profitability, NNNN's ROE is +0.27%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, NNNN is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
NNNN vs APR Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, APR has a market cap of 0. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas APR's P/E ratio is 22.59. In terms of profitability, NNNN's ROE is +0.27%, compared to APR's ROE of +9.81%. Regarding short-term risk, NNNN is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
NNNN vs IIN Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, IIN has a market cap of 0. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas IIN's P/E ratio is 226.45. In terms of profitability, NNNN's ROE is +0.27%, compared to IIN's ROE of -0.00%. Regarding short-term risk, NNNN is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
NNNN vs HRC Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, HRC has a market cap of 0. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas HRC's P/E ratio is 41.92. In terms of profitability, NNNN's ROE is +0.27%, compared to HRC's ROE of +0.14%. Regarding short-term risk, NNNN is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HRC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
NNNN vs ATRS Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ATRS's P/E ratio is 14.95. In terms of profitability, NNNN's ROE is +0.27%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, NNNN is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
NNNN vs IVTY Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas IVTY's P/E ratio is -3.80. In terms of profitability, NNNN's ROE is +0.27%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, NNNN is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
NNNN vs ALOG Comparison July 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 441.5M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, NNNN is priced at $9.90 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 145.38, whereas ALOG's P/E ratio is 40.93. In terms of profitability, NNNN's ROE is +0.27%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, NNNN is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ALOG's competition here